title: Five year trends in dyslipidaemia prevalence and management in Switzerland: the CoLaus study.
abstract: OBJECTIVE
  Data from prospective cohorts describing dyslipidaemia prevalence and treatment trends are lacking. Using data from the prospective CoLaus study, we aimed to examine changes in serum lipid levels, dyslipidaemia prevalence and management in a population-based sample of Swiss adults.
  
  
  RESULTS
  Cardiovascular risk was assessed using PROCAM. Dyslipidaemia and low-density lipoprotein cholesterol (LDL-C) target levels were defined according to the Swiss Group for Lipids and Atherosclerosis. Complete baseline and follow up (FU) data were available for n = 4863 subjects during mean FU time of 5.6 years. Overall, 32.1% of participants were dyslipidaemic at baseline vs 46.3% at FU (p < 0.001). During this time, lipid lowering medication (LLM) rates among dyslipidaemic subjects increased from 34.0% to 39.2% (p < 0.001). In secondary prevention, LLM rates were 42.7% at baseline and 53.2% at FU (p = 0.004). In multivariate analysis, LLM use among dyslipidaemic subjects, between baseline and FU, was positively associated with personal history of CVD, older age, hypertension, higher BMI and diabetes, while negatively associated with higher educational level. Among treated subjects, LDL-C target achievement was positively associated with diabetes and negatively associated with personal history of CVD and higher BMI. Among subjects treated at baseline, LLM discontinuation was negatively associated with older age, male sex, smoking, hypertension and parental history of CVD.
  
  
  CONCLUSIONS
  In Switzerland, the increase over time in dyslipidaemia prevalence was not paralleled by a similar increase in LLM. In a real-life setting, dyslipidaemia management remains far from optimal, both in primary and secondary prevention.
authors: Department of Internal Medicine, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. Electronic address: panagiotis.antiochos@gmail.com.
authors: P
authors: P
authors: Antiochos
authors: Department of Internal Medicine, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
authors: P
authors: P
authors: Marques-Vidal
authors: Department of Internal Medicine, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
authors: G
authors: G
authors: Waeber
authors: Department of Internal Medicine, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
authors: P
authors: P
authors: Vollenweider
mesh_terms: D000328:Adult; D000368:Aged; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood / Q000628:therapy; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D019468:Disease Management; D050171:Dyslipidemias / Q000097:blood / Q000453:epidemiology* / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000628:therapy; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012959:Socioeconomic Factors; D013557:Switzerland / Q000453:epidemiology; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides
keywords: Adherence; Dyslipidaemia; Lipid-lowering medication; Low-density lipoprotein cholesterol; Prospective cohort